Diabetes

Prediagnostic weight loss could be an important marker for colorectal cancer diagnosis.

The results of a review, published in Cureus, show that the medications reduced the risk of HF.

A severe reduction in food intake lasting just 2 weeks caused damage to the heart and kidneys that appeared to be irreversible, even after the body weight was restored.

Data from the aflibercept 8 mg clinical trial program will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting, April 23 to 27.

Findings show that study participants experienced improvements in both blood sugar control and the lipid profile.

A linear mixed-effect model for repeated estimated glomerular filtration rate measurements at baseline and a follow-up visit, up to 5 years after baseline, shows results.

The FDA’s temporary Guidance for 503A compounding of shortage drugs was meant to be temporary and withdrawn once COVID-19 ended.

Keeping blood glucose levels within a target range delays prevents serious health complications associated with type 2 diabetes.

It is important for pharmacists to educate patients, especially those with cardiovascular risks, about the differences between fish oil supplements and prescription n3-FAs products.

Expert discusses the updated guidelines for treating diabetes at the American Pharmacists Association (APhA) 2023 Meeting & Exposition in Phoenix, Arizona.

Health benefits last for at least 5 years if shedding pounds occur via a lifestyle change program, the results of a research review show.

Thought-provoking economic, ethical conundrums accompany recent explosion in growth of glucagon-like peptide-1 products for medically assisted weight loss

On March 1, 2023, Eli Lilly and Company said it would take steps to cap insulin prices, and Novo Nordisk and Sanofi followed suit 2 weeks later.

Asian Americans often develop the disease at a normal weight, which would be overlooked by current screening guidelines, investigators say.

CGM devices can also help individuals with diabetes make more informed decisions about their diet, exercise, and medication management, leading to improved overall health outcomes.

There has not yet been established a consensus on the set of factors to use for assessing social determinants of health in practice.

It is important for pharmacists to understand implications related to drug clearance to maximize therapeutics in patients with kidney disease.

Finerenone is a first in class nonsteroidal mineralocorticoid receptor antagonist indicated in adults with chronic kidney disease associated with type 2 diabetes mellitus.

The changes, which will be effective January 1, 2024, include pre-filled pens, vials of basal, vials of bolus, and pre-mix insulins.

Patients with diabetes who followed a plant-based, low-carbohydrate diet and participated in healthy lifestyle habits experienced the most health benefits.

Molecular complexes can serve as a D-glucose chemical sensor with chiral selectivity and sensitivity to improve diabetes testing.

The application is based on phase 3 results from the DINAMO trial showing that Jardiance tablets significantly reduced A1C levels vs a placebo in participants aged 10 to 17 years.

Donna Ryan, MD, discussed her presentation about pharmacological approaches for obesity, which patients they are indicated for, and considerations for pharmacists.

Pharmacists play a vital role in ensuring that patients can afford their medications, either by advising them on more affordable options or working with insurers and prescribers to find cheaper alternatives.

Although scientists have long been working on anti-obesity medications, several key failures in recent decades have made this a challenge.